Pterostilbene suppresses gastric cancer proliferation and metastasis by inhibiting oncogenic JAK2/STAT3 signaling: In vitro and in vivo therapeutic intervention

Pengzhan He; Yangbo Li; Jiaming Hu; Beiying Deng; Zongbiao Tan; Ying Chen; Baoping Yu; Weiguo Dong

doi:10.1016/j.phymed.2023.155316

Pterostilbene suppresses gastric cancer proliferation and metastasis by inhibiting oncogenic JAK2/STAT3 signaling: In vitro and in vivo therapeutic intervention

Phytomedicine. 2023 Dec 25:128:155316. doi: 10.1016/j.phymed.2023.155316. Online ahead of print.

Authors

Pengzhan He¹, Yangbo Li¹, Jiaming Hu¹, Beiying Deng¹, Zongbiao Tan¹, Ying Chen¹, Baoping Yu², Weiguo Dong³

Affiliations

¹ Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China; Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
² Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China. Electronic address: yubp62@163.com.
³ Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China. Electronic address: dongweiguo@whu.edu.cn.

PMID: 38518635
DOI: 10.1016/j.phymed.2023.155316

Abstract

Background: Gastric cancer (GC) represents a significant health burden with dire prognostic implications upon metastasis and recurrence. Pterostilbene (PTE) has been proven to have a strong ability to inhibit proliferation and metastasis in other cancers, while whether PTE exhibits anti-GC activity and its potential mechanism remain unclear.

Purpose: To explore the efficacy and potential mechanism of PTE in treating GC.

Methods: We employed a comprehensive set of assays, including CCK-8, EdU staining, colony formation, flow cytometry, cell migration, and invasion assays, to detect the effect of PTE on the biological function of GC cells in vitro. The xenograft tumor model was established to evaluate the in vivo anti-GC activity of PTE. Network pharmacology was employed to predict PTE's potential targets and pathways within GC. Subsequently, Western blotting, immunofluorescence, and immunohistochemistry were utilized to analyze protein levels related to the cell cycle, EMT, and the JAK2/STAT3 pathway.

Results: Our study demonstrated strong inhibitory effects of PTE on GC cells both in vitro and in vivo. In vitro, PTE significantly induced cell cycle arrest at G0/G1 and S phases and suppressed proliferation, migration, and invasion of GC cells. In vivo, PTE led to a dose-dependent reduction in tumor volume and weight. Importantly, PTE exhibited notable safety, leaving mouse weight, liver function, and kidney function unaffected. The involvement of the JAK2/STAT3 pathway in PTE's anti-GC effect was predicted utilizing network pharmacology. PTE suppressed JAK2 kinase activity by binding to the JH1 kinase structural domain and inhibited the downstream STAT3 signaling pathway. Western blotting confirmed PTE's inhibition of the JAK2/STAT3 pathway and EMT-associated protein levels. The anti-GC effect was partially reversed upon STAT3 activation, validating the pivotal role of the JAK2/STAT3 signaling pathway in PTE's activity.

Conclusion: Our investigation validates the potent inhibitory effects of PTE on the proliferation and metastasis of GC cells. Importantly, we present novel evidence implicating the JAK2/STAT3 pathway as the key mechanism through which PTE exerts its anti-GC activity. These findings not only establish the basis for considering PTE as a promising lead compound for GC therapeutics but also contribute significantly to our comprehension of the intricate molecular mechanisms underlying its exceptional anti-cancer properties.

Keywords: Gastric cancer; JAK2/STAT3; Metastasis; Proliferation; Pterostilbene.